Moving towards personalized medicine in rheumatoid arthritis
1 Department of Pathology, Section of Inflammatory Disease Profiling, VU University Medical Center, Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands
2 Department of Rheumatology, Section of Inflammatory Disease Profiling, VU University Medical Center, Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
Arthritis Research & Therapy 2014, 16:110 doi:10.1186/ar4565
See related research by Dennis et al., http://arthritis-research.com/content/16/2/R90Published: 19 May 2014
To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the clinical and molecular properties of the individual patients need to be well characterized. A crucial step in this approach is to discover subgroups of patients that are characterized by a good or poor treatment outcome. Dennis and colleagues have identified distinct pretreatment gene expression profiles in affected synovial tissue specimens and a tissue type-related systemic protein pattern which are associated with a positive or negative clinical outcome to monotherapy with adalumimab (anti-TNFα) and tocilizumab (anti-IL-6 receptor). These observations assign biological pathways associated with response outcome and provide evidence for the existence of systemic, easy-to-measure predictive biomarkers for clinical benefit of these biologics.